While oncology trials are becoming increasingly complex due to rare biomarkers, adaptive designs, patient recruitment delays, and limited tissue availability, liquid biopsy is changing the landscape. It can provide rapid and minimally invasive access to tumor’s genomics through circulating tumor DNA (ctDNA), offering crucial insights into a cancer’s identity and helping guide treatment selection. In this webinar, our scientific experts will discuss how liquid biopsy-enabled comprehensive genomic profiling (CGP) is driving smarter patient selection, adaptive trial designs, and dynamic biomarker strategies, thereby empowering biopharma teams to accelerate oncology drug development with greater precision and agility.
Key learning objectives include:
-
Expert perspective: overview of best practices for integrating CGP in clinical trials
-
Facilitating clinical trial enrollment
-
Identifying potential resistance mechanisms
-
Monitoring treatment response
-
Enabling personalized medicine